Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/42990
Campo DC Valoridioma
dc.contributor.authorDeiana, Valeriaen_US
dc.contributor.authorGómez-Cañas, Maríaen_US
dc.contributor.authorPazos, M. Ruthen_US
dc.contributor.authorFernández-Ruiz, Javieren_US
dc.contributor.authorAsproni, Battistinaen_US
dc.contributor.authorCichero, Elenaen_US
dc.contributor.authorFossa, Paolaen_US
dc.contributor.authorMuñoz, Eduardoen_US
dc.contributor.authorDeligia, Francescoen_US
dc.contributor.authorMurineddu, Gabrieleen_US
dc.contributor.authorGarcía-Arencibia, Moisésen_US
dc.contributor.authorPinna, Gerard A.en_US
dc.date.accessioned2018-11-21T11:59:19Z-
dc.date.available2018-11-21T11:59:19Z-
dc.date.issued2016en_US
dc.identifier.issn0223-5234en_US
dc.identifier.urihttp://hdl.handle.net/10553/42990-
dc.description.abstractPrevious studies have investigated the relevance and structure-activity relationships (SARs) of pyrazole derivatives in relation with cannabinoid receptors, and the series of tricyclic 1,4-dihydroindeno[1,2-c]pyrazoles emerged as potent CB2 receptor ligands. In the present study, novel 1,4-dihydroindeno[1,2-c]pyrazole and 1H-benzo[g]indazole carboxamides containing a cyclopropyl or a cyclohexyl substituent were designed and synthesized to evaluate the influence of these structural modifications towards CB1 and CB2 receptor affinities. Among these derivatives, compound 15 (6-cyclopropyl-1-(2,4-dichlorophenyl)-N-(adamantan-1-yl)-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide) showed the highest CB2 receptor affinity (Ki = 4 nM) and remarkable selectivity (KiCB1/KiCB2 = 2232), whereas a similar affinity, within the nM range, was seen for the fenchyl derivative (compound 10: Ki = 6 nM), for the bornyl analogue (compound 14: Ki = 38 nM) and, to a lesser extent, for the aminopiperidine derivative (compound 6: Ki = 69 nM). Compounds 10 and 14 were also highly selective for the CB2 receptor (KiCB1/KiCB2 > 1000), whereas compound 6 was relatively selective (KiCB1/KiCB2 = 27). The four compounds were also subjected to GTPγS binding analysis showing antagonist/inverse agonist properties (IC50 for compound 14 = 27 nM, for 15 = 51 nM, for 10 = 80 nM and for 6 = 294 nM), and this activity was confirmed for the three more active compounds in a CB2 receptor-specific in vitro bioassay consisting in the quantification of prostaglandin E2 release by LPS-stimulated BV2 cells, in the presence and absence of WIN55,212-2 and/or the investigated compounds. Modelling studies were also conducted with the four compounds, which conformed with the structural requirements stated for the binding of antagonist compounds to the human CB2 receptor.en_US
dc.languageengen_US
dc.publisher0223-5234-
dc.relation.ispartofEuropean Journal of Medicinal Chemistryen_US
dc.sourceEuropean Journal of Medicinal Chemistry [ISSN 0223-5234], v. 112, p. 66-80en_US
dc.subject32 Ciencias médicasen_US
dc.subject.otherCB(2) antagonismen_US
dc.subject.otherCannabinoid receptorsen_US
dc.subject.otherMolecular modellingen_US
dc.subject.otherSynthesisen_US
dc.subject.otherTricyclic pyrazolesen_US
dc.titleTricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB<inf>2</inf>receptor ligands with antagonist/inverse agonist propertiesen_US
dc.typeinfo:eu-repo/semantics/Articlees
dc.typeArticlees
dc.identifier.doi10.1016/j.ejmech.2016.02.005
dc.identifier.scopus2-s2.0-84981298101-
dc.identifier.isi000372558200007
dc.contributor.authorscopusid57194483512-
dc.contributor.authorscopusid47761206700-
dc.contributor.authorscopusid6701326923-
dc.contributor.authorscopusid7006533053-
dc.contributor.authorscopusid7801341853-
dc.contributor.authorscopusid23970379500-
dc.contributor.authorscopusid7004138079-
dc.contributor.authorscopusid7202348306-
dc.contributor.authorscopusid55241643800-
dc.contributor.authorscopusid6603506924-
dc.contributor.authorscopusid15821889300-
dc.contributor.authorscopusid35546140700-
dc.description.lastpage80-
dc.description.firstpage66-
dc.relation.volume112-
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngid3479936
dc.contributor.daisngid2056921
dc.contributor.daisngid1182976
dc.contributor.daisngid180726
dc.contributor.daisngid1475866
dc.contributor.daisngid749265
dc.contributor.daisngid31927177
dc.contributor.daisngid76495
dc.contributor.daisngid5628976
dc.contributor.daisngid974941
dc.contributor.daisngid1760567
dc.contributor.daisngid267952
dc.contributor.wosstandardWOS:Deiana, V
dc.contributor.wosstandardWOS:Gomez-Canas, M
dc.contributor.wosstandardWOS:Pazos, MR
dc.contributor.wosstandardWOS:Fernandez-Ruiz, J
dc.contributor.wosstandardWOS:Asproni, B
dc.contributor.wosstandardWOS:Cichero, E
dc.contributor.wosstandardWOS:Fossa, P
dc.contributor.wosstandardWOS:Munoz, E
dc.contributor.wosstandardWOS:Deligia, F
dc.contributor.wosstandardWOS:Murineddu, G
dc.contributor.wosstandardWOS:Garcia-Arencibia, M
dc.contributor.wosstandardWOS:Pinna, GA
dc.date.coverdateAbril 2016
dc.identifier.ulpgces
dc.description.sjr1,272
dc.description.jcr4,519
dc.description.sjrqQ1
dc.description.jcrqQ1
dc.description.scieSCIE
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.orcid0000-0002-1618-4487-
crisitem.author.fullNameGarcía Arencibia, Moisés-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

20
actualizado el 21-abr-2024

Citas de WEB OF SCIENCETM
Citations

19
actualizado el 25-feb-2024

Visitas

18
actualizado el 08-jul-2023

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.